About us

ApconiX are experts in ion channel biology, target safety assessments and in all aspects of nonclinical programme design and delivery.

ApconiX was formed by three AstraZeneca colleagues with the drive and ambition to create a world-renowned company founded on the skills and experience of a growing team with a wide range of expertise in nonclinical drug safety.

The model for the pharmaceutical industry has evolved in recent years with large pharma reducing internal capability and outsourcing key skills to trusted partners.  There are many more SMEs and academic groups who also need access to specialised services.

ApconiX addresses all needs by providing an exceptional group of scientists to these companies, in a cost-effective and flexible way.  In this way, companies work with people they trust, to make better decisions on drug safety.

Collaborating across the globe

The market need has been demonstrated by the remarkable growth of ApconiX. The current client list is spread across the globe.

ApconiX has embarked on several strategic international alliances.  In collaborating with the French company PhysioStim, ApconiX has become part of a European centre of excellence for preclinical cardiovascular safety evaluation.  The recent alliance with Sygnature Discovery ensures the Nottingham based CRO can provide its customers with a broader range of drug discovery services.

ApconiX is continually forming collaborative relationships, helping customers large and small. The changing face of drug discovery and development means a safe pair of hands is needed to help companies navigate the difficult pathway towards safe, effective and profitable drugs.

Apconix Evolution Timeline

Apconix Evolution Timeline
2019
May

Ian, Kim, Russell and William join the team

Ian, Kim, Russell and William join the team
Four new members of ApconiX as the team goes from strength to strength
March

ApconiX Celebrates Opening Swedish Office

ApconiX Celebrates Opening Swedish Office
Dr Michael Morton, Professor Ruth Roberts and Dr Richard Knight flew to Sweden to celebrate the opening of ApconiX AB in Gothenburg by sharing coffee and cake (fika) with our fellow tenants in the BioVentureHub. Experienced toxicologists Drs Steffen Ernst and Björn Dahl, who are based at the new Swedish office, joined the three Directors..Read More
2018
November

Phumzile and Karin Join the ApconiX Team

Phumzile and Karin Join the ApconiX Team
ApconiX is delighted to welcome two new members of the team
May

A growing team

A growing team
The team grows to 16-strong, providing an immense depth and breadth of knowledge to the field of nonclinical safety toxicology and ion channel electrophysiology.
2017
December

Start-Up of the Year 2017!

Start-Up of the Year 2017!
ApconiX wins BioNow Start-Up of the Year Award 2017.
September

Alliance with PhysioStim

Alliance with PhysioStim
ApconiX announce an alliance with PhysioStim based in France, creating a new Centre of Excellence dedicated to cardiac safety offering a range of services in nonclinical cardiovascular electrophysiology.
2016
November

Our First Employee

Our First Employee
ApconiX welcomes its first employee.
July

Chancellor’s visit

Chancellor’s visit
The U.K. Chancellor of the Exchequer, Rt Hon George Osborne visits ApconiX.
March

Grand opening

Grand opening
New office and laboratory opened by Professor Graham Boulnois with guests Prof Lewis Smith, Chris Doherty and Prof Iain Purchase
2015
July

Trading begins

Trading begins
ApconiX starts trading.
2014
December

ApconiX Ltd

ApconiX Ltd
ApconiX Ltd is formed.
October

BioHub Next Business Generation Programme

BioHub Next Business Generation Programme
Ruth, Rich and Mike win the BioHub Next Business Generation Programme.
2013
December

Discussions

Discussions
Ruth, Rich and Mike discuss starting a new company.

Want to know more?